1.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
by Kakkar, Ajay K, Prof
The Lancet (British edition), 2008, Vol.372 (9632), p.31-39
2.
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation
by Miller, Corey S., BA
The American journal of cardiology, 2012, Vol.110 (3), p.453-460
3.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
by Turpie, Alexander GG, MD
The Lancet (British edition), 2009, Vol.373 (9676), p.1673-1680
4.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
by Mega, JL, MD
The Lancet (British edition), 2009, Vol.374 (9683), p.29-38
5.
6.
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism
by Eriksson, Bengt I
Annual review of medicine, 2011, Vol.62 (1), p.41-57
7.
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
by Laliberté, François
Current medical research and opinion, 2014, Vol.30 (7), p.1317-1325
8.
Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
by Lee, Soyon, PharmD
The American journal of cardiology, 2012, Vol.110 (6), p.845-851
9.
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
by Powles, Thomas
Nature medicine, 2021, Vol.27 (5), p.793-801
10.
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compar...
by Washam, Jeffrey B, Pharm D
The Lancet (British edition), 2015, Vol.385 (9985), p.2363-2370
11.
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
by Santini, Daniele, Dr
The lancet oncology, 2012, Vol.13 (10), p.1020-1024
12.
Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan
by Yoshimura, Yukihiro
European journal of clinical microbiology & infectious diseases, 2020, Vol.39 (9), p.1637-1640
13.
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination
by Poyurovsky, Michael
Psychopharmacology, 2012, Vol.226 (3), p.615-622
14.
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals
by Crawford, Andrew A
Psychopharmacology, 2014, Vol.231 (15), p.2921-2931
15.
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation
by Nelson, Winnie W
Current medical research and opinion, 2014, Vol.30 (12), p.2461-2469
16.
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
by Lip, Gregory Y.H
Clinical therapeutics, 2014, Vol.36 (2), p.192-210.e20
17.
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
by Wong, Florence
Gut, 2012, Vol.61 (1), p.108-116
18.
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia
by Dahl, E.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (7), p.619-626
19.
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
by Cho, Byoung Chul
Future oncology (London, England), 2022, Vol.18 (6), p.639-647
20.
Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation
by Aryal, Madan Raj, MD
The American journal of cardiology, 2014, Vol.114 (4), p.577-582
